Who are SGLT2 Inhibition's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LG-group, Invokana Pill, oral hypoglycemic agents, Canagliflozin - SGLT2i, Oral administration of Ipragliflozin, Weight Based Group.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sglt2-inhibition.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SGLT2 Inhibition — Competitive Intelligence Brief

SGLT2 Inhibition (SGLT2 Inhibition) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SGLT2 inhibitor. Area: Diabetes.

marketed SGLT2 inhibitor SGLT2 (Sodium-Glucose Cotransporter 2) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

SGLT2 Inhibition (SGLT2 Inhibition) — Zhongshan Hospital Xiamen University. SGLT2 inhibitors block sodium-glucose cotransporter 2 in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SGLT2 Inhibition TARGET	SGLT2 Inhibition	Zhongshan Hospital Xiamen University	marketed	SGLT2 inhibitor	SGLT2 (Sodium-Glucose Cotransporter 2)
LG-group	LG-group	Medical University of Vienna	marketed	SGLT2 inhibitor	SGLT2
Invokana Pill	Invokana Pill	AgelessRx	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
oral hypoglycemic agents	oral hypoglycemic agents	Queen Elizabeth II Health Sciences Centre	marketed	Oral hypoglycemic agents (multiple classes: sulfonylureas, meglitinides, biguanides, thiazolidinediones, DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors)
Canagliflozin - SGLT2i	Canagliflozin - SGLT2i	Royal Devon and Exeter NHS Foundation Trust	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Oral administration of Ipragliflozin	Oral administration of Ipragliflozin	Asan Medical Center	marketed	SGLT2 inhibitor	SGLT2 (sodium-glucose cotransporter 2)
Weight Based Group	Weight Based Group	University of Colorado, Denver	marketed	SGLT2 inhibitor	SGLT2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SGLT2 inhibitor class)

Daewon Pharmaceutical Co., Ltd. · 13 drugs in this class
Qilu Pharmaceutical Co., Ltd. · 10 drugs in this class
Takeda · 10 drugs in this class
Taejoon Pharmaceutical Co., Ltd. · 9 drugs in this class
Hanmi Pharmaceutical Company Limited · 9 drugs in this class
Addpharma Inc. · 9 drugs in this class
GlaxoSmithKline · 7 drugs in this class
AO GENERIUM · 7 drugs in this class
Merck Sharp & Dohme LLC · 7 drugs in this class
Nobelpharma · 6 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SGLT2 Inhibition — Competitive Intelligence Brief. https://druglandscape.com/ci/sglt2-inhibition. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab